X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (28) 28
electricity (27) 27
chemistry (26) 26
metallurgy (26) 26
basic electric elements (24) 24
electric solid state devices not otherwise provided for (24) 24
semiconductor devices (24) 24
chemotherapy (23) 23
humans (23) 23
oncology (23) 23
organic chemistry (22) 22
female (21) 21
male (20) 20
aged (18) 18
cancer (18) 18
heterocyclic compounds (18) 18
middle aged (17) 17
pancreatic cancer (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
metastasis (12) 12
adhesives (11) 11
dyes (11) 11
materials for miscellaneous applications, not provided forelsewhere (11) 11
miscellaneous applications of materials (11) 11
miscellaneous compositions (11) 11
natural resins (11) 11
paints (11) 11
polishes (11) 11
survival (11) 11
adult (10) 10
gastroenterology & hepatology (10) 10
oxaliplatin (10) 10
colorectal cancer (9) 9
treatment outcome (9) 9
trial (9) 9
analysis (8) 8
care and treatment (8) 8
folfirinox (8) 8
pancreatic neoplasms - drug therapy (8) 8
aged, 80 and over (7) 7
cancer research (7) 7
disease-free survival (7) 7
fluorouracil (7) 7
gemcitabine (7) 7
general tagging of cross-sectional technologies spanning over several sections of the ipc (7) 7
general tagging of new technological developments (7) 7
irinotecan (7) 7
medicine & public health (7) 7
pancreatic neoplasms - pathology (7) 7
retrospective studies (7) 7
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (7) 7
carcinoma (6) 6
colorectal neoplasms - drug therapy (6) 6
deoxycytidine - analogs & derivatives (6) 6
leucovorin (6) 6
medical research (6) 6
metastases (6) 6
5-fluorouracil (5) 5
acyclic or carbocyclic compounds (5) 5
adenocarcinoma (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
bevacizumab (5) 5
cancer therapies (5) 5
colorectal neoplasms - pathology (5) 5
compositions based thereon (5) 5
confidence intervals (5) 5
deoxycytidine - administration & dosage (5) 5
drug combinations (5) 5
japan (5) 5
organic macromolecular compounds (5) 5
organoplatinum compounds - administration & dosage (5) 5
pharmacology & pharmacy (5) 5
phase-iii trial (5) 5
physics (5) 5
prognosis (5) 5
research (5) 5
survival rate (5) 5
their preparation or chemical working-up (5) 5
therapy (5) 5
tumors (5) 5
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic agents - therapeutic use (4) 4
cancer patients (4) 4
clinical trials (4) 4
drug therapy (4) 4
fluorouracil - therapeutic use (4) 4
inflammation (4) 4
leucovorin - therapeutic use (4) 4
macromolecular compounds obtained otherwise than by reactionsonly involving unsaturated carbon-to-carbon bonds (4) 4
pathology (4) 4
patients (4) 4
reduction of greenhouse gas [ghg] emissions, related to energygeneration, transmission or distribution (4) 4
surgery (4) 4
technologies or applications for mitigation or adaptation againstclimate change (4) 4
1st-line treatment (3) 3
adenocarcinoma - drug therapy (3) 3
adjuvant treatment (3) 3
animals (3) 3
antineoplastic agents - administration & dosage (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_5
Abstract Background Although gemcitabine plus nab–paclitaxel (GnP) is a standard treatment for advanced pancreatic cancer as the result of phase III trial... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue suppl 4, pp. iv59 - iv59
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2012, Volume 23, Issue suppl 11, pp. xi99 - xi131
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2018, Volume 13, Issue 9, p. e0203386
Journal Article
by Boscari, F and Messori, M and Rabbone, I and Rabbone, I and Bonfanti, R and Sabbion, A and Iafusco, D and Schiaffini, R and Visentin, R and Visentin, R and Calore, R and Leal, Y and Galasso, S and Galasso, S and Galderisi, A and Vallone, V and Di Palma, F and Losiouk, E and Lanzola, G and Tinti, T and Rigamonti, A and Marigliano, M and Zanfardino, A and Rapini, N and Avogaro, A and Chernavvsky, D and Magni, L and Cobelli, C and Bruttomesso, D and Kovatchev, B and Barnard, K and Bergenstal, R and Laffel, L and Weissberg-Benchell, J and Hood, K and Heinemann, L and Sullivan, S and Miller, K.M and Frontino, G and Rigamonti, A and Bonura, C and Favalli, V and Breton, M and Lepore, G and Bonfanti, R and Bonfanti, R and Bozzetto, L and Di Blasi, V and Girelli, A and Grassi, G and Iafusco, D and Rabbone, I and Schiaffini, R and Laviola, L and Minuto, N and Ignaccolo, G and Iafusco, D and Lombardo, F and Cherubini, V and Frongia, A.P and Pistorio, A and Marigliano, M and Toni, S and Scaramuzza, A.E and Forlenza, G and Wadwa, R.P and Messer, L and Bequette, B.W and Cameron, F and Howsmon, D and Huyett, L and Dassau, E and Doyle, F.J and Patek, S and Schertz, E and Mauritzen, E and Mandell, A and DeSalvo, D and Ly, T.T and Buckingham, B.A and Festa, C and Bongiovanni, M and Mattei, L and Colatrella, A and Stewart, Z and Pate, T and Danne, T and Kordonouri, O and Kordonouri, O and Kordonouri, O and Lange, K and Spaniolas, K and Wohlgemuth, S.D and Stefan, D and Homan, M and Orel, R and Battelino, T and Sinha-Gregory, S and Gerber, L and Ferrari, M and ...
Diabetes Technology & Therapeutics, ISSN 1520-9156, 02/2016, Volume 18, Issue S1, pp. A-1 - A-140
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue suppl 4, pp. iv77 - iv77
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2017, Volume 140, Issue 4, pp. 973 - 982
We investigated peptide cocktail vaccine OCV‐C01 containing epitope peptides derived from KIF20A, vascular endothelial growth factor receptor (VEGFR)1 and... 
adjuvant therapy | pancreatic cancer | KIF20A | predictive marker | peptide vaccine | FACTOR RECEPTOR 1 | TUMOR | RANDOMIZED CONTROLLED-TRIAL | HLA-A | EPITOPE-PEPTIDES | CHEMOTHERAPY | GEMCITABINE | HEPATOCELLULAR-CARCINOMA | MELANOMA | ONCOLOGY | GROWTH | Humans | Middle Aged | Neoplasm Proteins - immunology | Immunotherapy, Active | Male | Vascular Endothelial Growth Factor Receptor-2 - immunology | Carcinoma, Pancreatic Ductal - surgery | Epitopes - immunology | Cancer Vaccines - therapeutic use | Deoxycytidine - therapeutic use | Vaccines, Subunit - therapeutic use | Peptide Fragments - immunology | Vascular Endothelial Growth Factor Receptor-1 - immunology | Aged, 80 and over | Female | Chemotherapy, Adjuvant | Carcinoma, Pancreatic Ductal - immunology | T-Lymphocytes, Cytotoxic - immunology | HLA-A24 Antigen - immunology | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - surgery | Kaplan-Meier Estimate | Pancreatectomy | Carcinoma, Pancreatic Ductal - therapy | Combined Modality Therapy | Kinesin - immunology | Cancer Vaccines - immunology | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Pancreatic Neoplasms - immunology | T-Cell Antigen Receptor Specificity | Aged | Deoxycytidine - analogs & derivatives | Pancreatic Neoplasms - therapy | Cancer patients | Peptides | Pancreatic cancer | Adjuvant treatment | Clinical trials | Product development | Vaccines | T cells | Vascular endothelial growth factor | Cancer | Antigenic determinants | Pharmaceutical industry
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue suppl 4, pp. iv67 - iv67
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2019, Volume 30, Issue Supplement_9
Abstract Background In the NAPOLI-1 phase 3 trial, nal-IRI+5-FU/LV significantly increased median PFS (mPFS) vs 5-FU/LV (3.1 vs 1.5 months [mo], unstratified... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_5
Abstract Background Axitinib (AX) is an orally administered selective inhibitor of vascular endothelial growth factor (VEGF) receptor (R)-1/2/3. We previously... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2016, Volume 27, Issue suppl 2, pp. ii16.1 - ii16
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2014, Volume 25, Issue suppl_4, pp. iv179 - iv180
Abstract Aim: Tri-weekly XELIRI is not completely regarded as a valid substitute for FOLFIRI in mCRC because of the potential for greater toxicity. Reduced... 
Journal Article
by Horikawa, Y and Tsuchiya, N and Yuasa, K and Narita, S and Saito, M and Takayama, K and Nara, T and Tsuruta, H and Obara, T and Numakura, K and Satoh, S and Habuchi, T and Hu, X and Guo, J and Lin, Z and Sun, L and Xu, Z and Cang, C and Wang, G and Kanda, T and Sakamoto, K and Matsuki, A and Ohashi, R and Hirota, S and Fujimori, Y and Matsuda, Y and Yajima, K and Kosugi, S and Hatakeyama, K and Kitahara, K and Watanabe, M and Nakazono, S and Wada, N and Kakizaki, H and Li, J and Gong, F. J and Sun, P. N and Shen, L and Li, Q and Li, N and Qiu, M and Liu, J and Yi, C and Luo, D and Li, Z and Gou, H and Yang, Y and Cao, D and Shen, Y and Wang, X and Xu, F and Bi, F and Zhang, X and Wei, W and Luo, H. Y and Wang, Z. Q and Wang, F. H and Qiu, M. Z and Teng, K. Y and Ruan, D. Y and He, Y. J and Li, Y. H and Xu, R. H and Matsusaka, S and Mizunuma, N and Suenaga, M and Shinozaki, E and Mishima, Y and Terui, Y and Hatake, K and Nara, E and Kodaira, M and Yokoyama, M and Saotome, T and Takahashi, S and Nishimura, N and Nakano, K and Ueda, K and Yamada, S and Nozawa, M and Mochida, Y and Nishigaki, K and Nagae, S and Uemura, H and Oh, S. Y and Jeong, C. Y and Hong, S. C and Lee, W. S and Kim, H. G and Lee, G.-W and Hwang, I. G and Jang, J. S and Kwon, H.-C and Kang, J. H and Ozaka, M and Ogura, M and Chin, K and Pua, P. F and Ganzon, D and Chan, V and ... and The Western Cooperative Gastrointestinal Oncology Group of China From the Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 03/2011, Volume 41, Issue 3, pp. i6 - i17
Journal Article
Journal Article
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN 0344-5704, 06/2018, Volume 81, Issue 6, pp. 1017 - 1023
We evaluated the efficacy and safety of a modified FOLFIRINOX regimen for chemotherapy-na < ve patients with metastatic pancreatic cancer. Patients with... 
FOLFIRINOX | LEUCOVORIN | Modified FOLFIRINOX | OXALIPLATIN | GEMCITABINE | BREAST-CANCER | TRIAL | Chemotherapy | CABAZITAXEL | ONCOLOGY | Pancreatic cancer | COLORECTAL-CANCER | PHARMACOLOGY & PHARMACY | Metastatic | RESISTANT PROSTATE-CANCER | JAPANESE PATIENTS
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2013, Volume 24, Issue suppl 4, pp. iv92 - iv93
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2013, Volume 24, Issue suppl 4, pp. iv34 - iv34
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.